Author(s): Bhandare N, Kennedy L, Malyapa RS, Morris CG, Mendenhall WM
Abstract Share this page
Abstract PURPOSE: To investigate the incidence of radiotherapy (RT)-induced central and primary hypothyroidism regarding total dose, fractionation, and adjuvant chemotherapy. METHODS AND MATERIALS: We retrospectively reviewed the data from 312 patients treated with RT for extracranial head-and-neck tumors between 1964 and 2000. The cervical lymph nodes were irradiated in 197 patients. The radiation doses to the thyroid gland and hypothalamic-pituitary axis were estimated by reconstructing the treatment plans. RESULTS: Clinical central hypothyroidism (CH) was observed in 17 patients (5.4\%); the median clinical latency was 4.8 years. Clinical primary hypothyroidism (PH) was observed in 40 patients (20.3\%); the median clinical latency was 3.1 years. Multivariate analysis of clinical CH revealed that fractionation, adjuvant chemotherapy, and total dose to the pituitary were not significant. Multivariate analysis of clinical PH revealed that the total dose to the thyroid (p = 0.043) was significant, but adjuvant chemotherapy, age, and gender were not. Of the patients tested for hypopituitarism, 14 (20.3\%) of 69 demonstrated subclinical CH and 17 (27.4\%) of 62 demonstrated subclinical PH. The 5-year and 10-year rates of freedom from clinical CH and PH were 97\% and 87\% and 68\% and 67\%, respectively. Of the patients tested, the 5-year and 10-year rates of freedom from subclinical CH and PH were 91\% and 78\% and 71\% and 71\%, respectively. CONCLUSION: Clinical and subclinical manifestations of late radiation toxicity were observed in the thyroid and hypothalamic-pituitary axis. Although CH did not indicate a dependence on fractionation, adjuvant chemotherapy, or total dose to the pituitary, PH showed a dependence on the total dose to the thyroid gland.
This article was published in Int J Radiat Oncol Biol Phys
and referenced in Atherosclerosis: Open Access